Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders for Acurx Pharmaceuticals, Inc. held on July 17, 2025. The record date for the meeting was May 27, 2025. At that time, there were 23,481,606 shares of common stock outstanding. Approximately 74.38% of outstanding shares were represented at the meeting, establishing a quorum.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and stockholder votes. It does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. Investors should refer to the company's most recent Form 10-K or 10-Q for financial statements.
Material Changes and Voting Results
Stockholders voted on six proposals. All proposals were approved. Key outcomes include:
- Proposal 1 (Election of Directors): Carl V. Sailer and Thomas Harrison were elected as Class I directors.
- Proposal 2 (Auditor Ratification): CohnReznick LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Proposal 3 (Reverse Stock Split): Stockholders approved an amendment to effect a reverse stock split at a ratio between 1:10 and 1:30, with the specific ratio and timing to be determined by the Board of Directors.
- Proposal 4 (Warrant Exercise): Approved the issuance of shares underlying Series F Warrants and Wainwright Warrants to comply with Nasdaq Listing Rule 5635(d).
- Proposal 5 (ELOC Approval): Approved the issuance of shares to Lincoln Park Capital Fund, LLC under a Purchase Agreement dated May 8, 2025, to comply with Nasdaq Listing Rule 5635(d).
- Proposal 6 (Equity Plan Increase): Approved an increase in shares available under the 2021 Equity Incentive Plan from 177,448 to 2,677,448.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors. The approval of the reverse stock split and significant warrant/LOC issuances suggests the company is taking measures to maintain Nasdaq listing compliance and secure capital, which may involve dilution to existing shareholders.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and implementation date once announced by the Board.
- Review the definitive Proxy Statement filed on May 29, 2025, for detailed terms of the Wainwright Warrants and Lincoln Park ELOC.
- Monitor the impact of the approved share issuances (Warrants and ELOC) on total share count and potential dilution.
- Check subsequent filings for the updated share count following the reverse stock split.